Hepatitis C: Magnitude of the problem

Liver Transplantation

Volumn 8, Issue 10 SUPPL. 1, 2002, Pages s3-s6

  Rakela, Jorge ^a   Vargas, Hugo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LYMPHOCYTE ANTIBODY; RIBAVIRIN;

ALCOHOL LIVER DISEASE; ARTICLE; CANCER RISK; CHOLESTATIC HEPATITIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; FATTY LIVER; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS VIRUS; HIGH RISK PATIENT; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; RECURRENT INFECTION; REOPERATION; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES;

EID: 0036795544     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.35855     Document Type: Article

References (54)

1. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569.
2. Davis GL, Albright JE, Cook S, Rosenberg D. Projecting the future healthcare burden from hepatitis C in the United States [abstract]. Hepatology 1998;82:390A.
3. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, GaW N, et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000;284:450-456.
4. . Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002;9:235-241.
5. Lieber CS. Liver diseases by alcohol and hepatitis C: Early detection and new insights in pathogenesis lead to improved treatment. Am J Addict 2001; 10(suppl):S29-S50.
6. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
7. Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatitis-Hepatitis C virus in HIV coinfection. Am J Gastroenterol 2002;97:478-483.
8. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: Clinical issues in coinfection. Am J Med 1999;107(suppl): S79-S84.
9. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999;179: 1254-1258.
10. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-247.
11. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002;29:378-387.
12. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
13. Sansone GR, Frengley JD. Impact of HAART on causes of death of persons with late-stage AIDS. J Urban Health 2000;77:166-175.
14. Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001;72:1684-1688.
15. Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001;72:177-181.
16. Taniguchi M, Shakil AO, Vargas HE, Laskus T, Demetris AJ, Gayowski T, et al. Clinical and virological outcomes of hepatitis B and C viral coinfection after liver transplantation: Effect of viral hepatitis D. Liver Transpl 2000;6:92-96.
17. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62-65.
18. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
19. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-3230.
20. AchkarJP, Araya V, Baron RL, Marsh JW, Dvorchik I, Rakela J. Undetected hepatocellular carcinoma: Clinical features and outcome after liver transplantation. Liver Transpl Surg 1998;4:477-482.
21. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
22. Rosen HR. Retransplantation for hepatitis C: Implications of different policies. Liver Transpl 2000;6(suppl):S41-S46.
23. Pappo O, Ramos H, Starzl TE, Fung JJ, Demetris AJ. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995;19:192-206.
24. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
25. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
26. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-1143.
27. Berenguer M, Rayon JM, Prieto M, Aguilera V, Nicolas D, Ortiz V, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001;7:790-796.
28. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999;29:250-256.
29. Feray C, Caccamo, L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
30. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122: 889-896.
31. Forns X, Ampurdanes S, Sanchez-Tapias JM, Guilera M, Sans M, Sanchez-Fueyo A, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001;35:265-271.
32. Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, Sanchez-Tapias JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002;73:56-63.
33. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369.
34. Charlton M. Patient and graft survival following liver transplantation for hepatitis C: Much ado about something. Gastroenterology 2002;122:1162-1165.
35. Charlton M. Genotype 1b and severity of posttransplant recurrence of hepatitis C infection-Unconvictable felon or wrongly accused? Liver Transpl 2000;6:243-245.
36. Graziadei IW, Wiesner RH, Marotta PJ, Porayko, MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-1127.
37. Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29:1220-1226.
38. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
39. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
40. Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H, et al. Cutaneous injection of RANTES causes eosinophil recruitment: Comparison of nonallergic and allergic human subjects. J Immunol 1997;159:2962-2972.
41. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE, Clavien PA. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000;6:407-412.
42. Taniguchi M, Wachs M, Bak T, Trotter J, Kugelmas M, Everson G, Kam I. Hepatitis C recurrence in living donor liver transplantation [abstract]. Am J Transplant 2002;2:138.
43. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.
44. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001;33:1355-1357.
45. Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, et al. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-521.
46. Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838.
47. Bizollon T, Ducerf C, Baulieux J, Trepo C. Treatment of recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep 1999;1:15-19.
48. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-504.
49. Lavezzo B, Rizzetto M. Treatment of recurrent hepatitis C virus infection after liver transplantation. J Hepatol 1999;31(suppl 1):S222-S226.
50. Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001;7:870-876.
51. Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-190.
52. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997;112:575-582.
53. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;6:1612-1616.
54. Ahmed A, Keeffe EB. Hepatitis C virus and liver transplantation. Clin Liver Dis 2001;5:1073-1090.